Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis

Bone

Volumn 48, Issue 2, 2011, Pages 202-211

  Hussein, Osama ^a,b   Tiedemann, Kerstin ^a   Komarova, Svetlana V ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Bisphosphonates; Bone metastases; Breast cancer; Osteoclast

Indexed keywords

ALENDRONIC ACID; BIM PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; MACROPHAGE ACTIVATING FACTOR; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PHOSPHOLIPASE C;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL COUNT; CELL CULTURE; CELL LINE; CELL SIZE; CELL STRAIN RAW264.7; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; UPREGULATION;

ALENDRONATE; ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DIPHOSPHONATES; FEMALE; HUMANS; IMMUNOBLOTTING; MICE; MICROSPECTROPHOTOMETRY; OSTEOCLASTS; POLYMERASE CHAIN REACTION;

EID: 78650972753     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.09.006     Document Type: Article

References (68)

1. Hess K.R., Varadhachary G.R., Taylor S.H., Wei W., Raber M.N., Lenzi R., et al. Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633.
2. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987, 55:61-66.
3. Boyde A., Maconnachie E., Reid S.A., Delling G., Mundy G.R. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc 1986, 1537-1554.
4. Taube T., Elomaa I., Blomqvist C., Beneton M.N., Kanis J.A. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994, 15:161-166.
5. Stenbeck G. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol 2002, 13:285-292.
6. Lu X., Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007, 12:153-162.
7. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
8. Chen Y.C., Sosnoski D.M., Gandhi U.H., Novinger L.J., Prabhu K.S., Mastro A.M. Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcinogenesis 2009, 30:1941-1948.
9. Kinder M., Chislock E., Bussard K.M., Shuman L., Mastro A.M. Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 2008, 314:173-183.
10. Morgan H., Tumber A., Hill P.A. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004, 109:653-660.
11. Guo Y., Tiedemann K., Khalil J.A., Russo C., Siegel P.M., Komarova S.V. Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 2008, 43:386-393.
12. Mancino A.T., Klimberg V.S., Yamamoto M., Manolagas S.C., Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001, 100:18-24.
13. Tiedemann K., Hussein O., Sadvakassova G., Guo Y., Siegel P.M., Komarova S.V. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways. J Biol Chem 2009, 284:33662-33670.
14. Gallet M., Sevenet N., Dupont C., Brazier M., Kamel S. Breast cancer cell line MDA-MB 231 exerts a potent and direct anti-apoptotic effect on mature osteoclasts. Biochem Biophys Res Commun 2004, 319:690-696.
15. Gallet M., Mentaverri R., Sevenet N., Brazier M., Kamel S. Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. Apoptosis 2006, 11:1909-1921.
16. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986, 261:12665-12674.
17. Dallas S.L., Rosser J.L., Mundy G.R., Bonewald L.F. Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 2002, 277:21352-21360.
18. Siclari V.A., Guise T.A., Chirgwin J.M. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 2006, 25:621-633.
19. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
20. Pouliot F., Blais A., Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003, 63:277-281.
21. Yoshimura N., Sano H., Hashiramoto A., Yamada R., Nakajima H., Kondo M., et al. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 1998, 89:28-34.
22. Okunieff P., Fenton B.M., Zhang L., Kern F.G., Wu T., Greg J.R., et al. Fibroblast growth factors (FGFS) increase breast tumor growth rate, metastases, blood flow, and oxygenation without significant change in vascular density. Adv Exp Med Biol 2003, 530:593-601.
23. Liu J.F., Crepin M., Liu J.M., Barritault D., Ledoux D. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 2002, 293:1174-1182.
24. Beslija S., Bonneterre J., Burstein H.J., Cocquyt V., Gnant M., Heinemann V., et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20:1771-1785.
25. Kataja V., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl 2):ii11-ii13.
26. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007, 86:1022-1033.
27. van B.E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108-111.
28. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
29. Levine J.P. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 2006, 8:40-53.
30. Gainford M.C., Dranitsaris G., Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005, 330:769-773.
31. Josse R.G., Hanley D.A., Kendler D., Ste Marie L.G., Adachi J.D., Brown J. Diagnosis and treatment of Paget's disease of bone. Clin Invest Med 2007, 30:E210-E223.
32. Zhang Q., Badell I.R., Schwarz E.M., Boulukos K.E., Yao Z., Boyce B.F., et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 2005, 52:2708-2718.
33. Armstrong S., Pereverzev A., Dixon S.J., Sims S.M. Activation of P2X7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts. J Cell Sci 2009, 122:136-144.
34. Xing L., Boyce B.F. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 2005, 328:709-720.
35. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
36. Akchurin T., Aissiou T., Kemeny N., Prosk E., Nigam N., Komarova S.V. Complex dynamics of osteoclast formation and death in long-term cultures. PLoS One 2008, 3:e2104.
37. Sugatani T., Hruska K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005, 280:3583-3589.
38. Rose A.A., Pepin F., Russo C., Abou Khalil J.E., Hallett M., Siegel P.M. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007, 5:1001-1014.
39. Ross F.P. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann N Y Acad Sci 2006, 1068:110-116.
40. Ross F.P., Teitelbaum S.L. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005, 208:88-105.
41. Lau Y.S., Danks L., Sun S.G., Fox S., Sabokbar A., Harris A., et al. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Res Treat 2007, 105:7-16.
42. Komarova S.V., Pilkington M.F., Weidema A.F., Dixon S.J., Sims S.M. RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts. J Biol Chem 2003, 278:8286-8293.
43. Tanaka S., Miyazaki T., Fukuda A., Akiyama T., Kadono Y., Wakeyama H., et al. Molecular mechanism of the life and death of the osteoclast. Ann N Y Acad Sci 2006, 1068:180-186.
44. Houde N., Chamoux E., Bisson M., Roux S. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J Biol Chem 2009, 284:23397-23404.
45. Akiyama T., Bouillet P., Miyazaki T., Kadono Y., Chikuda H., Chung U.I., et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 2003, 22:6653-6664.
46. Akiyama T., Dass C.R., Choong P.F. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009, 8:3173-3180.
47. Tan T.T., Degenhardt K., Nelson D.A., Beaudoin B., Nieves-Neira W., Bouillet P., et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005, 7:227-238.
48. von M.I., Krebbel H., Hecht M., Manz R.A., Fleissner C., Mieth M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007, 21:2025-2034.
49. Zhang Q., Badell I.R., Schwarz E.M., Boulukos K.E., Yao Z., Boyce B.F., et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 2005, 52:2708-2718.
50. Woo K.M., Kim H.M., Ko J.S. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med 2002, 34:340-346.
51. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
52. Wakeyama H., Akiyama T., Takahashi K., Amano H., Kadono Y., Nakamura M., et al. Negative feedback loop in the Bim-caspase-3 axis regulating apoptosis and activity of osteoclasts. J Bone Miner Res 2007, 22:1631-1639.
53. Sutherland K.A., Rogers H.L., Tosh D., Rogers M.J. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009, 11:R58.
54. Yagiz K., Rittling S.R. Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res 2009, 315:2442-2452.
55. Dib I.E., Gressier M., Salle V., Mentaverri R., Brazier M., Kamel S. Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. Leuk Res 2008, 32:1279-1287.
56. Hiraga T., Nakamura H. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int J Cancer 2009, 124:215-222.
57. Negishi-Koga T., Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 2009, 231:241-256.
58. Nakamura I., Lipfert L., Rodan G.A., Le T.D. Convergence of alpha(v)beta(3) integrin- and macrophage colony stimulating factor-mediated signals on phospholipase Cgamma in prefusion osteoclasts. J Cell Biol 2001, 152:361-373.
59. Epple H., Cremasco V., Zhang K., Mao D., Longmore G.D., Faccio R. Phospholipase Cgamma2 modulates integrin signaling in the osteoclast by affecting the localization and activation of Src kinase. Mol Cell Biol 2008, 28:3610-3622.
60. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83:1032-1045.
61. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209-257.
62. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007, 7(Suppl 1):S14-S20.
63. Lipton A., Cook R., Saad F., Major P., Garnero P., Terpos E., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
64. Lipton A., Cook R.J., Major P., Smith M.R., Coleman R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
65. Zuradelli M., Masci G., Biancofiore G., Gullo G., Scorsetti M., Navarria P., et al. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. Oncologist 2009, 14:548-556.
66. Lipton A., Steger G.G., Figueroa J., Alvarado C., Solal-Celigny P., Body J.J., et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008, 14:6690-6696.
67. Lipton A., Steger G.G., Figueroa J., Alvarado C., Solal-Celigny P., Body J.J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007, 25:4431-4437.
68. Body J.J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221-1228.